Brentuximab vedotin: an anti-CD30 antibody-drug conjugate (Q38091629)

28 August 2017

title

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate (English)

1 reference

28 August 2017

Amber M Bradley

1

1 reference

28 August 2017

Meghan Devine

series ordinal

2

1 reference

28 August 2017

David DeRemer

series ordinal

3

1 reference

28 August 2017

publication date

1 April 2013

1 reference

American Journal of Health-System Pharmacy

28 August 2017

published in

1 reference

28 August 2017

volume

70

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

589-597

1 reference

28 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Standard therapy of advanced Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

How I treat relapsed and refractory Hodgkin lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

CD30: an important new target in hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Anti-CD30 Antibodies for Hodgkin lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Antibody-drug conjugates: targeted drug delivery for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Revised response criteria for malignant lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Vinorelbine in the treatment of lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Treatment of refractory T-cell malignancies using gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110608

31 March 2020

Identifiers

DOI

10.2146/AJHP110608

1 reference

28 August 2017

1 reference